Beetroot Juice Can Reduce Central Sympathetic Outflow

This article originally appeared here.
Share this content:
Beetroot Juice Can Reduce Central Sympathetic Outflow
Beetroot Juice Can Reduce Central Sympathetic Outflow

FRIDAY, May 19, 2017 (HealthDay News) -- Acute dietary nitrate supplementation using beetroot (BR) juice can decrease central sympathetic outflow at rest and during exercise, according to a study published online May 5 in the American Journal of Physiology-Heart and Circulatory Physiology.

Karambir Notay, from the University of Guelph in Canada, and colleagues conducted blood pressure and muscle sympathetic nerve activity (MSNA) measurements before and after ingestion of high-nitrate BR or nitrate-depleted BR placebo in a randomized cross-over study involving 14 participants. The authors also obtained blood pressure and MSNA measures during two minutes of static handgrip.

The researchers found that following BR versus placebo, the changes in resting MSNA burst frequency (−3 ± 5 versus 3 ± 4 bursts/min; P = 0.001) and burst incidence (−4 ± 7 versus 4 ± 5 bursts/100 heartbeats; P = 0.002) were lower, whereas there were no differences in systolic (−1 ± 5 versus 2 ± 5 mm Hg; P = 0.30) and diastolic blood pressure (4 ± 5 versus 5 ± 7 mm Hg; P = 0.68) and spontaneous arterial sympathetic baroreflex sensitivity (P = 0.95). The change in MSNA burst incidence was lower following BR versus placebo during static handgrip (1 ± 8 versus 8 ± 9 bursts/100 heartbeats; P = 0.001), while there were no significant differences in MSNA burst frequency and systolic and diastolic blood pressure.

"Dietary nitrate supplementation may represent a novel intervention to target exaggerated sympathetic outflow in clinical populations," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths